Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New 24-Hour infusion shows promise for advanced Parkinson's

NCT ID NCT04379050

Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing the long-term safety of ABBV-951, a drug given as a continuous 24-hour infusion under the skin for people with advanced Parkinson's disease. About 130 adults who completed an earlier study will continue receiving the treatment. Researchers will monitor side effects, infusion site reactions, and changes in symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ABBV-951 (foscarbidopa/foslevodopa)
What this could lead to
If successful, this could provide a new, continuous treatment option to better control motor symptoms in advanced Parkinson's disease.
What could go wrong
This is an open-label extension with no placebo group, so results may be less reliable. Side effects like infusion site reactions, hallucinations, and weight loss are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

130 people

The number who actually took part.

Started

Jun 2020

Finished

Apr 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants who have Parkinson's Disease and who have successfully completed the parent study M15-741. * Participants willing and able to comply with procedures required in the protocol. Exclusion Criteria: \- Participants, if judged by the investigator to be unsuitable candidates to continue to receive ABBV-951 for any reason.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson's disease (PD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson's disease (PD)

Contacts and locations

Locations

  • Aarhus Universitetshospital - Skejby /ID# 215392

    Aarhus, Central Jutland, 8200, Denmark

  • Academician I.P. Pavlov First St. Petersburg State Medical University /ID# 218869

    Saint Petersburg, Sankt-Peterburg, 197101, Russia

  • Azienda Ospedale-Universita Padova /ID# 215421

    Padova, 35128, Italy

  • Banner Sun Health Research Institute /ID# 215579

    Sun City, Arizona, 85351, United States

  • Baylor College of Medicine /ID# 215401

    Houston, Texas, 77030, United States

  • Bispebjerg and Frederiksberg Hospital /ID# 215391

    Copenhagen NV, Capital Region, 2400, Denmark

  • Booth Gardner Parkinson's Care Center /ID# 215535

    Kirkland, Washington, 98034-3029, United States

  • Central Texas Neurology Consul /ID# 217013

    Round Rock, Texas, 78681, United States

  • City Clinical Hospital #40 /ID# 218870

    Sestroretsk, Sankt-Peterburg, 197706, Russia

  • Clinique Neuro Levis /ID# 215371

    Lévis, Quebec, G6W 0M5, Canada

  • Complejo Hospitalario Universitario A Coruña /ID# 215426

    A Coruña, A Coruna, 15006, Spain

  • Concord Repatriation General Hospital /ID# 215943

    Concord, New South Wales, 2139, Australia

  • Dartmouth-Hitchcock Medical Center /ID# 216834

    Lebanon, New Hampshire, 03756, United States

  • Derriford Hospital and the Royal Eye Infirmary /ID# 217390

    Plymouth, Devon, PL6 8DH, United Kingdom

  • Duplicate_Algemeen Ziekenhuis Sint-Jan Brugge /ID# 215686

    Bruges, West-Vlaanderen, 8000, Belgium

  • Duplicate_Groupe Sante CHC - Clinique du MontLegia /ID# 215685

    Liège, 4000, Belgium

  • Duplicate_Osaka University Hospital /ID# 217415

    Suita-shi, Osaka, 565-0871, Japan

  • Duplicate_Royal Adelaide Hospital /ID# 215940

    Adelaide, South Australia, 5000, Australia

  • Hospital General Universitario de Elche /ID# 215425

    Elche, Alicante, 03203, Spain

  • Hospital Santa Creu i Sant Pau /ID# 215429

    Barcelona, 08041, Spain

  • Hospital Universitari de Bellvitge /ID# 215427

    L'Hospitalet de Llobregat, Barcelona, 08907, Spain

  • Hospital Universitario Virgen de las Nieves /ID# 215431

    Granada, 18014, Spain

  • Hospital Universitario Virgen del Rocio /ID# 215428

    Seville, 41013, Spain

  • IRCCS Centro Neurolesi Bonino Pulejo /ID# 215422

    Messina, 98124, Italy

  • Indiana Clinical Research Cent /ID# 216490

    Indianapolis, Indiana, 46202, United States

  • Inland Northwest Research /ID# 215533

    Spokane, Washington, 99202-1342, United States

  • Karolinska Universitetssjukhuset - Huddinge /ID# 215386

    Huddinge, Stockholm County, 141 57, Sweden

  • Kings College Hospital NHS Foundation Trust /ID# 217388

    London, Greater London, SE5 9RS, United Kingdom

  • Kliniken Beelitz GmbH /ID# 215403

    Beelitz-Heilstätten, 14547, Germany

  • Legacy Medical Group - Neurology /ID# 215536

    Portland, Oregon, 97232-2003, United States

  • M3 Wake Research - Raleigh /ID# 215596

    Raleigh, North Carolina, 27612-8106, United States

  • NHS Tayside /ID# 217389

    Dundee, Scotland, DD2 1UB, United Kingdom

  • National Center of Neurology and Psychiatry /ID# 218763

    Kodaira-shi, Tokyo, 187-8551, Japan

  • National Hospital Organization Asahikawa Medical Center /ID# 218762

    Asahikawa-shi, Hokkaido, 070-8644, Japan

  • Odense University Hospital /ID# 215390

    Odense, Region Syddanmark, 5000, Denmark

  • Parkinson's Disease and Movement Disorders Center of Boca Raton /ID# 215412

    Boca Raton, Florida, 33486, United States

  • Perron Institute /ID# 215944

    Nedlands, Western Australia, 6009, Australia

  • Sahlgrenska Universitetssjukhuset /ID# 215387

    Gothenburg, Västra Götaland County, 413 46, Sweden

  • Skane University Hospital Lund /ID# 215385

    Lund, Skåne County, 224 84, Sweden

  • St. Antonius Ziekenhuis, Locatie Utrecht /ID# 215396

    Utrecht, 3543 AZ, Netherlands

  • The Alfred Hospital /ID# 215942

    Melbourne, Victoria, 3004, Australia

  • Univ Kansas Med Ctr /ID# 215624

    Kansas City, Kansas, 66160, United States

  • Univ Texas HSC San Antonio /ID# 215400

    San Antonio, Texas, 78229-3901, United States

  • Universitaetsklinikum Ulm /ID# 215405

    Ulm, Baden-Wurttemberg, 89081, Germany

  • Universitair Ziekenhuis Leuven /ID# 215684

    Leuven, Vlaams-Brabant, 3000, Belgium

  • University of Alabama at Birmingham - Main /ID# 215597

    Birmingham, Alabama, 35233, United States

  • University of Calgary /ID# 215369

    Calgary, Alberta, T2N 4Z6, Canada

  • University of Colorado Hospital /ID# 215625

    Aurora, Colorado, 80045, United States

  • Washington University-School of Medicine /ID# 215472

    St Louis, Missouri, 63110, United States

  • Westmead Hospital /ID# 215941

    Westmead, New South Wales, 2145, Australia

  • curiositas ad sanum /ID# 215404

    Haag i.OB, Bavaria, 83527, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.